LaVigne K, et al. - In women with recurrent ovarian cancer, researchers compared the effects of prophylactic, extended carboplatin infusion vs standard infusion on the rate of carboplatin hypersensitivity reactions (HSRs). They conducted a single-institution, randomized, nonblinded trial comparing a graded, 3-hour extended infusion of carboplatin vs a standard 30-minute infusion in patients with recurrent ovarian cancer enrolled from January 2011 to April 2015. No association of a prophylactic, extended carboplatin infusion with a decreased HSR rate was noted. Findings revealed an overall low HSR rate, suggesting premedication could be helpful in reducing HSRs.